Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 14/20 | 0.60 |
| ▸ | KDR | P35968 | 11/20 | 0.60 |
| ▸ | AURKA | O14965 | 6/20 | 0.57 |
| ▸ | FLT1 | P17948 | 5/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296802 | 0.87 | FLT3 (0.53) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296747 | 0.87 | KDR (0.53) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296803 | 0.87 | FLT3 (0.53) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296824 | 0.87 | KDR (0.58) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296788 | 0.87 | FLT3 (0.54) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296793 | 0.87 | KDR (0.54) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296762 | 0.85 | FLT3 (0.52) | FLT3KDRAURKAFLT1ALK | |
| SCHEMBL21296819 | 0.82 | MCHR1 (0.54) | FLT3KDRAURKAFLT1MCHR1 | |
| SCHEMBL21296795 | 0.82 | MCHR1 (0.50) | FLT3KDRAURKAMCHR1BRD4 | |
| SCHEMBL29937831 | 0.81 | MCHR1 (0.55) | FLT3KDRAURKAFLT1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | IL6, IL6ST, IL2 | FLT3 244/4885KDR 1820/4885AURKA 2424/4885 |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | FLT3 339/4885KDR 1797/4885AURKA 3483/4885 |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | IL6, IL6ST, IL2 | FLT3 244/4885KDR 1820/4885AURKA 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.